The effects of Helicobacter pylori eradication on chemokine production in patients with immune thrombocytopenic purpura.
Nomura
Shosaku
S
Inami
Norihito
N
Kanazawa
Shigenori
S
D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000097:blood* / Q000150:complications; D018925:Chemokines / Q000096:biosynthesis* / Q000097:blood; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood* / Q000150:complications
D000897:Anti-Ulcer Agents; D018925:Chemokines; D000658:Amoxicillin; D011239:Prednisolone; D017291:Clarithromycin; D009853:Omeprazole